Results 161 to 170 of about 3,203 (180)

Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation

European Journal of Pharmacology, 2012
Soo Yeon Joo, Chang Seong Kim, Joon Seok Choi   +2 more
exaly  

Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial

American Journal of Kidney Diseases, 2009
Steven Fishbane
exaly  

Paricalcitol

Drugs, 2012
Dean M Robinson, Lesley J Scott, Robinson Dean M   +2 more
exaly  

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

Lancet, The, 2010
Dick De Zeeuw, Rajiv Agarwal, Paul Audhya   +2 more
exaly  

PARICALCITOL IMPROVES ERYTHROPOIETIN RESPONSIVENESS

ASAIO Journal, 2003
S B Shuja, R M Raja
openaire   +1 more source

Paricalcitol, a Vitamin D Receptor Activator, Inhibits Tumor Formation in a Murine Model of Uterine Fibroids

Reproductive Sciences, 2014
Sunil K Halder, Ayman Al-Hendy, Halder Sunil K   +2 more
exaly  

Paricalcitol.

2011
openaire   +1 more source

Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-α and IL-8 production by human peripheral blood mononuclear cells

International Urology and Nephrology, 2009
Theodoros Eleftheriadis, Georgia Antoniadi, Vassilios Liakopoulos   +2 more
exaly  

Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2

Nephrology Dialysis Transplantation, 2013
Hyeon Seok Hwang, Keum Jin Yang, Sungyoup Hong   +2 more
exaly  

Paricalcitol for Treatment of Secondary Hyperparathyroidism in CKD Patients

American Journal of Kidney Diseases, 2006
Tilman B, Drüeke, Paul, Landais
openaire   +2 more sources